Interim Analysis of a Phase II Trial of Montelukast for the Treatment of Bronchiolitis Obliterans Syndrome After HSCT Reveals Immunobiology of Disease
Year: 2013
Type: article
Study design: Clinical Trial
Abstract: Bronchiolitis obliterans syndrome (BOS) after allogeneic HSCT is associated with high mortality and unknown pathogenesis. We present interim results from a prospective phase II trial evaluating of montelukast for the treatment of BOS after HSCT and studying BOS biology. Montelukast interrupts cysteinyl leukotriene activity and may diminish homing of activated cells to bronchioles and fibrosis. Twenty-three patients have enrolled with stable or decreasing immunosuppression for 3 months prior and BOS diagnosed by modified NIH criteria; 2 were withdrawn, and 19 have completed primary endpoint.
Authors: Kirsten M. Williams, Steven Z. Pavletic, Stephanie J. Lee, Candice Cottle-Delisle, Fran Hakim, Beryl Manning-Geiss, Sandra Mitchell, Juan Gea-Banacloche, Leora Comis, Edward W. Cowen, Kristin Baird, James H. Shelhamer, Daniel Fowler, Bazetta A.J. Blacklock-Schuver, Daniele Avila, Ronald Gress
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W1983731464